FDA Approves CRISPR Therapy Casgevy for Children as Young as 2 With Sickle Cell Disease

Sickle cell disease can begin destroying organs before a child turns two, but no gene therapy reached that far until now. The FDA's July 1 approval of Casgevy extends the world's first CRISPR cure to children as young as two, covering roughly 5,500 newly eligible US patients.